PreveCeutical Medical (TSE:PREV) has released an update.
PreveCeutical Medical Inc. has announced the filing of its audited annual financial statements for 2023 and expects to file its Q1 Filings by July 5, 2024, subsequent to which it anticipates the revocation of a voluntary management cease trade order. The company is following alternative information guidelines and confirms no material changes since its last default announcement. PreveCeutical is advancing in the preventive health sciences sector with ongoing development and commercialization efforts for its innovative therapies.
For further insights into TSE:PREV stock, check out TipRanks’ Stock Analysis page.
